Canada’s risk-averse regulatory environment and unpredictable drug access and pricing are pushing clinical trials abroad, leaving patients without the novel medicines they need. To reclaim its standing in global health innovation, experts argue the country must embrace regulatory flexibility and agility, provide patients with access to clinical trials, standardize drug pricing, and create dedicated pathways for made-in-Canada health technologies.